N4 PHARMA PLC — Director's Dealing 2018

Sep 26, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0390C

N4 Pharma PLC

26 September 2018

26 September 2018

N4 Pharma Plc

("N4 Pharma" or the "Company")

Grant of options

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company, announces that the Company has today granted a total of 1,004,000 options over ordinary shares in the Company ("Ordinary Shares") to certain members of senior management pursuant to the Company's unapproved share options scheme (the "Options"). The Options have been granted as follows:

Name	Options over Ordinary Shares previously held	Number of Options granted	Total number of options over Ordinary Shares now held
Allen Hey, Head of CMC Program Development, Biologics	0	717,143	717,143
Andrew Leishman, Head of Nuvec Development	0	286,857	286,857

The Options have an exercise price of 6.60p, which was the closing mid-market price of an Ordinary Share in the Company on 25 September 2018, being the day prior to the grant, and can be exercised from three years up until ten years from the date of grant.  Following this grant of Options, there are a total of 7,249,084 options outstanding over Ordinary Shares and 11,054,071 warrants outstanding over Ordinary Shares.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Allen William Hey

2

Reason for the notification

a)

Position/status

Head of CMC Program Development, Biologics, a PDMR

b) 

Initial notification /Amendment

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

N4 Pharma plc

b)

LEI

213800OIN8T68PM7HK77

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.4p each in N4 Pharma PLC

Identification code (ISIN) for N4 Pharma PLC ordinary shares:

GB00BYW8QM32

b)

Nature of the transaction

Grant of options 

c)

Price(s) and volume(s)

Price(s)	Volume(s)
Exercise price of 6.6p	717,143

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

26 September 2018

f)

Place of the transaction

Outside a trading venue

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Andrew Leishman

2

Reason for the notification

a)

Position/status

Head of Nuvec Development, a PDMR

b) 

Initial notification /Amendment

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

N4 Pharma plc

b)

LEI

213800OIN8T68PM7HK77

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.4p each in N4 Pharma PLC

Identification code (ISIN) for N4 Pharma PLC ordinary shares:

GB00BYW8QM32

b)

Nature of the transaction

Grant of options 

c)

Price(s) and volume(s)

Price(s)	Volume(s)
Exercise price of 6.6p	286,857

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

26 September 2018

f)

Place of the transaction

Outside a trading venue

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO	Via Alma PR
Allenby Capital Limited James Reeve/Virginia Bull/Asha Chotai	Tel: +44(0)203 328 5656
Alma PR Josh Royston Robyn Fisher	Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHLFMTTMBITBFP